Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in obese PCOS
NCT06595797Phase 2Not yet recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of HRS9531 in polycystic ovary syndrome (PCOS) and obesity (3 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Percentage change in body weight from baseline at 32 weeks. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
HRS9531
03
Conditions
polycystic ovary syndrome (PCOS)obesity
Beyond the preview
Go deeper on NCT06595797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06595797.